



## Product Data Sheet

---

<b>Product Name:</b>	Proapoptotic Peptide, (klaklak) <sub>2</sub>	
<b>Catalog Number:</b>	AS-62199 (0.5 mg)	<b>Lot Number:</b> See label on vial
<b>Sequence:</b>	H-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-NH <sub>2</sub> (3-letter code) klaklakklaklak-NH <sub>2</sub> (1-letter code)	
<b>Molecular Weight:</b>	1523.0	
<b>Peptide Purity:</b>	>95%	
<b>Appearance:</b>	Lyophilized white powder	

**Peptide Reconstitution:** Proapoptotic peptide is freely soluble in water.

**Storage:** Proapoptotic peptide is shipped at ambient temperature. Upon receipt, store lyophilized peptide at –20°C or lower. Reconstituted peptide can be aliquoted and stored at –20°C or lower.

**Additional Information:** Listed below are relevant information that may provide a guideline on how to use this product. End users will have to adapt to their own specific applications.

The synthetic peptides CGSPGWVRC, CGSPGWVRC-GG-D(KLAKLAK)<sub>2</sub>, and D(KLAKLAK)<sub>2</sub> were obtained commercially (AnaSpec; San Jose, CA) to our specifications. In some binding experiments, as indicated, a synthetic cyclic peptide (sequence CARAC) served as an unrelated negative control. *In Vitro Cell Viability and Cell Apoptosis Assays*—Cells (2 × 10<sup>4</sup> cells/well) were seeded in 96-well plates for 24 h in 10% FBS in DMEM, incubated with increasing concentrations of the peptides CGSPGWVRC-GG-D(KLAKLAK)<sub>2</sub> or CGSPGWVRC and D(KLAKLAK)<sub>2</sub> in 80 µl of 1% FBS in DMEM for 6 hours at 37 °C. After 6 h, cell viability was measured with a cell proliferation detection reagent according to the manufacturer's instructions (WST-1; Roche Applied Science)- [Giordano, R. et al. J Biol Chem 283, 29447 \(2008\).](#)

Soluble CGRRAGGSC-GG-D(KLAKLAK)<sub>2</sub>, CGRRAGGSC, and D(KLAKLAK)<sub>2</sub> peptides, and the unrelated control peptide CKGGRAKDC-GG-D(KLAKLAK)<sub>2</sub>, were synthesized to our specifications by AnaSpec (San Jose, CA). NCaP, MDA-PCa-2b cells (each at 3 × 10<sup>4</sup>/well), and EF43. *fgf-4* cells ([7](#)) at 2 × 10<sup>4</sup>/well were seeded in triplicates and incubated in 96-well plates (Becton Dickinson, Franklin Lakes, NJ) for 24–72 h at 37°C, with serially increasing concentrations (10–100 µM) of CGRRAGGSC-GG-D(KLAKLAK)<sub>2</sub> peptide, CGRRAGGSC peptide alone, D(KLAKLAK)<sub>2</sub> peptide alone, or an equimolar mixture of the unconjugated peptides CGRRAGGSC and D(KLAKLAK)<sub>2</sub>. LNCaP cells were also exposed in parallel to increasing concentrations (20–100 µM) of CGRRAGGSC-GG-D(KLAKLAK)<sub>2</sub> and unrelated control peptides CKGGRAKDC-GG-D(KLAKLAK)<sub>2</sub> or CGSPGWVRC-GG-D(KLAKLAK)<sub>2</sub>, under the same conditions-[Zurita, A. et al. Cancer Res 64, 435 \(2004\).](#)

Published Citations:

Zurita, A. et al. *Cancer Res* **64**, 435 (2004).  
Giordano, R. et al. *J Biol Chem* **283**, 29447 (2008).  
Nie, J. et al. *Stem Cells* **26**, 2735 (2008).

Related Products:

<b>Name</b>	<b>Cat #</b>	<b>Size</b>
Pro-apoptotic Peptide, klaklakklaklak, 5-FAM-labeled 5-FAM-klaklakklaklak-NH2	AS-62206	1 mg

*For Research Use Only*